Kornimate/medical-research-clean huggingface dataset:
oral zinc gluconate as treatment for recalcitrant cutaneous warts: a randomized, double-blind, placebo-controlled trial

Conditions: Recalcitrant Cutaneous Warts

Summary: up to one-third of common warts can remain recalcitrant, an occurrence that has been attributed to impaired cell-mediated immunity. at present, no guidelines exist for the management of recalcitrant cutaneous warts. zinc, a well-established immunomodulatory agent, has shown promise in this regard. previous studies documenting the efficacy of oral zinc used zinc sulfate given at a maximum dose of 600 mg/day, equivalent to 140 mg of elemental zinc, which is over three times the recommended upper limit of 40 mg of elemental zinc per day. this raises concerns over safety and tolerability. in the philippines, oral zinc is more widely available in chelated forms such as zinc gluconate, which have the benefit of improved absorption compared to non-chelated compounds such as zinc sulfate. this study will seek to determine if zinc gluconate 300 mg/day, equivalent to 40 mg of elemental zinc, will be efficacious in treating recalcitrant cutaneous warts. this lowered dose may have the added benefits of increased safety, tolerability, and cost-effectiveness.


Eligibility criteria:
inclusion criteria: 1. male or non-pregnant female 2. age 19 years and older 3. with ≥ one (1) recalcitrant common, mosaic, palmar, plantar, or periungual wart/s 4. consent given exclusion criteria: 1. current or history of mental illness 2. current or history of malignancy 3. severe immunodeficiency states 4. pregnant or lactating 5. documented adverse effects to oral or topical zinc exposure 6. oral intake of zinc supplements in the past 12 months or less 7. oral intake of h2 antagonists in the past 4 weeks or less 8. oral intake of immunosuppressives in the past 4 weeks or less 9. concurrent usage of other treatment modalities 10. current anogenital warts

Keywords: recalcitrant cutaneous warts verruca
ezetrol® re-examination study (mk0653-175)(completed)

Conditions: Hypercholesterolemia

Summary: this survey is conducted for preparing application materials for re-examination under the pharmaceutical affairs laws and its enforcement regulation, its aim is to reconfirm the clinical usefulness of ezetrol® through collecting the safety information according to the re-examination regulation for new drugs.


Eligibility criteria:
inclusion criteria: * participants who receives ezetrol® in usual medical practice

Keywords: hypercholesterolemia
strengthening maternal neonatal and child health services in a rural district of pakistan

Conditions: Antepartum Hemorrhage; Postpartum Hemorrhage; Anemia; Eclampsia; Neonatal Sepsis; Birth Asphyxia; Diarrhoea; Pneumonia

Summary: the maternal neonatal and child health indicators in district dadu of pakistan portrays a dismal pictures and after the floods of 2010-2011 the health infrastructure of this district was badly affected. aga khan university pakistan is intending to implement a service delivery project for the improvement of maternal neonatal and child health situation through evidence based mnch interventions.

the aga khan university is implementing together with its local partners a mnch project in five union councils (uc) in dadu district in sindh province. the project will scale up the already existing health services for mnch in the district referral hospital and the five basic health units (bhus), one in each uc. institutional based services as well as their scope for outreach to pregnant women, mothers and children in the communities with the aim to promote safe deliveries as per who guidelines and government policy will be enhanced. in order to deliver quality services, the facilities will be renovated and equipped and the capacity of the existing staff will be strengthened through different training courses in mnch. in addition professionally trained lady health visitors will be introduced in the bhus, who will conduct all maternal services including deliveries in the bhu and the communities. the health staff is furthermore responsible to establish and facilitate community support groups and raise communal awareness for the importance of mother and child health care as well as safe deliveries with skilled attendants. operational research is an integral part of this pilot project. the research validates the progress and improvement of maternal and child health indicators. the results will be used to lobby the scale up of mnch interventions with the ministry of health in pakistan.

Eligibility criteria:
inclusion criteria: * be a resident of target areas and consent to participate in the study exclusion criteria: * do not fulfill the residence and consent criteria
effect of long-term psoriasis on patients' life - coronate

Conditions: Psoriasis

Summary: psoriasis, is an inflammatory chronic skin disease which has a heavy physical and psychosocial impact on participant's life. this is a study to finalize and validate a questionnaire to assess the long-term effect of long-term psoriasis in adult participants. approximately 550 adult participants with moderate to severe plaque psoriasis will be enrolled in approximately 15 dermatology centers in italy. participants will receive standard of care while participating in this study. no drug will be administered as a part of this study. the duration of this study is up to 22 months. there is no additional burden for participants in this study. participants will attend regular visits during the course of the study at a hospital or clinic.


Eligibility criteria:
inclusion criteria: * participants with a diagnosis of moderate-to-severe plaque psoriasis (pasi≥10 or pasi\<10 with involvement of sensitive areas) since at least 10 years. * adult partner in relationship with the participant since at least 3 years(part 2 only). exclusion criteria: - participants with psychiatric conditions.

Keywords: psoriasis coronate questionnaire
trial of ire in cholangiocarcinoma

Conditions: Cholangiocarcinoma

Summary: the purpose of this study is to test any good and bad side effects of surgery using ire to treat cancer of the bile duct.


Eligibility criteria:
inclusion criteria: * age 18 years or older * capable of providing written and oral informed consent in english * locally advanced disease based on preoperative work-up demonstrating that the tumor is unresectable due to portal vein, hepatic artery, and/or bile duct involvement, insufficient hypertrophy response of the future liver remnant after portal vein embolization, or patients not able to tolerate major liver surgery * found to be unresectable intraoperatively based on vascular, biliary, or lymph node (n2) involvement upon exploratory laparotomy * patients will be assessed for chemotherapy prior to treatment with ire, but given the common problem of recurrent cholangitis, some patients will not be candidates for chemotherapy until after ire is performed. exclusion criteria: * locally advanced phc eligible and accepted for liver transplantation evaluation * phc with \> 5 cm extension along the common hepatic duct or common bile duct on preoperative imaging or intraoperative ultrasound * metastases to peritoneum, liver or other organs confirmed by percutaneous biopsy, staging laparoscopy or intraoperative frozen section * lymph node metastases beyond n2 stations, confirmed by intraoperative frozen sections or radiographic diagnosis * history of cardiac disease: * congestive heart failure (nyha class \>2) * active coronary artery disease (defined as myocardial infarction within 6 months prior to screening) * cardiac arrhythmias requiring anti-arrhythmic therapy or pacemaker (beta blockers are permitted) * any implanted stimulation device (defined as implantable cardiac device and a pacemaker) * uncontrolled hypertension (blood pressure must be ≤160/95 mmhg at the time of screening on a stable antihypertensive regimen) * uncontrolled infections (\> grade 2 nci-ctc, version 3.0) * epilepsy * both narrowing (sclerosis) of the main portal vein and a reduced diameter of either the common hepatic artery, celiac trunk or superior mesenteric artery of \>50%

Keywords: intraoperative use of ire 18-489
development of a novel functional eye-tracking software application for multiple sclerosis

Conditions: Multiple Sclerosis

Summary: this study aims to develop and validate a sensitive and non-invasive eye-tracking software application. this study will obtain participant responses to brief cognitive tests designed to evaluate several key functions known to be affected by ms and non-invasive eye movement measurements in response to visually presented stimuli during specifically designed eye-tracking tests. the study data will be used to develop machine learning algorithms and validate a software application intended to track the progressive component of multiple sclerosis and associated cognitive changes.


Eligibility criteria:
inclusion criteria: * able to provide informed consent. * aged 18 years or older at the time of enrollment. * able to read in either french or english. * visual acuity of 20/100 in at least one eye (corrective glasses, contact lenses, surgery etc. are permitted) for patients only: * confirmed diagnosis of ms with no signs of progressive increase in physical disability within the past six months. * neurological condition is medically stable during the study visit. * expanded disability status scale (edss) score 0 - 8.0 at the initial visit. exclusion criteria: * evidence or medical history of psychiatric issues that are known to also affect movements and oculomotor control. * presence of co-morbid neurological conditions to avoid eye movement anomaly confounds (strabismus, cranial nerve palsy, stroke-causing hemianopsia). * diagnosis of macular edema or other pre-existing ocular conditions that would prevent a participant from performing the eye movement assessments. * recent (less than three months from enrollment) start of, change of dose, or irregular use of, new prescription drugs known to influence ocular motor visual function, such as benzodiazepines, antipsychotics and anticonvulsants. occasional use of benzodiazepines for medical procedures is permitted, at the investigator's discretion, but should not occur within a short time period prior to or during an eye movement assessment. for healthy controls only: * evidence or history of significant neurodegenerative disorder affecting brain function, e.g., multiple sclerosis (ms), parkinson's disease (pd), amyotrophic lateral sclerosis (als), dementia. for ms patients only * diagnosis of clinically isolated syndrome (cis), radiologically isolated syndrome (ris) or primary progressive ms (ppms). * patients who are currently experiencing a relapse or who have experienced a relapse within the last three months. a relapse is defined as appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event (mcdonald et al. 2001). the abnormality must have been present for at least 24 hours and occurred in the absence of fever (\< 37.5°c) or known infection. * patients who have been undergoing disease-modifying therapy for less than three months
museum prescription by a physician for a visit to the mbam

Conditions: Quality of Life; Social Isolation

Summary: in recent years, museums have participated in the patient care journey by using art to enhance their quality of life and well-being. since 2015, the montreal museum of fine arts (mmfa) and dr. beauchet have developed an action-research program exploring the effects of participatory art activities for community elders conducted at the mmfa, known as the arts \& longevity lab (all). the mandate of all is to improve the well-being, quality of life and health (i.e. mental and physical state) of individuals and patients through the practice of visual arts activities (i.e. arts that produce objects perceived by the eyes). since 2019, the mmfa has developed in collaboration with médecins francophones du canada museum visits prescribed by a primary care physician as a new intervention. today, it is necessary to improve the knowledge on the effects of this museum visit prescription the overall objective of this study is to examine the effects of a visit to the mmfa prescribed by a primary care physician on the mental health (well-being and quality of life) of patients living in montreal.


Eligibility criteria:
inclusion criteria: * age 18 and over * having internet access at home with an electronic device (computer, keyboard, or smartphone) * having no dementia * speaking english or french * committing to visiting the museum within 3 months of the prescription. exclusion criteria: * individuals participating in a clinical trial at the same time, to avoid interference with the results of the intervention being studied in this protocol * individuals with dementia. there are no tests for dementia. the physicians involved in the pre-recruitment process are aware of the cognitive status of their patients. therefore, they will be able to avoid offering the study to a patient with dementia if such a diagnosis appears in the medical file.

Keywords: arts well-being mental health
long-term study of cerebral glucose metabolism in huntington's disease

Conditions: Huntington's Disease

Summary: objectives: i. correlate clinical outcome with cerebral glucose metabolism in patients with huntington's disease (hd) and their at-risk relatives. ii. evaluate the efficacy of cerebral glucose metabolism in observing the pathophysiologic development of hd, monitoring responses to experimental therapy, and predicting hd genotype. iii. identify, define, and describe the natural history of pathophysiologic lesions in hd. iv. characterize the genotypic and phenotypic expression of the hd gene.

protocol outline: participants are screened for huntington's disease, including cerebral glucose metabolism assessment and genetic testing. studies include a detailed family history and neurologic, psychometric, and neurobehavioral evaluations. imaging includes positron emission tomography with fluorodeoxyglucose and brain magnetic resonance imaging. a genotype assessment is performed; genetic results are not disclosed to patients or relatives.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- * documented family history of huntington's disease (hd) * symptomatic hd: chorea required * at-risk for hd: no detectable systemic or oculomotor abnormality * age-matched control subjects * no history of inherited neurological disease * no general or neurologic abnormality --prior/concurrent therapy-- at least 4 weeks since other hd treatment, e.g.: * haloperidol * benzodiazepine * other tranquilizers or neuroleptics --patient characteristics-- * no pregnant women

Keywords: huntington's disease neurologic and psychiatric disorders rare disease
a 12/24-weeks, open, multi-centre, phase iv study on safety and efficacy of 2mg exenatide once weekly (bydureon) in t2dm patients.

Conditions: Type 2 Diabetes Mellitus

Summary: as current study is conducted to provide additional information regarding safety and efficacy bydureon, exenatide once weekly for injectable suspension, in the korean population open label, non-comparative, multi-centre design is used.


Eligibility criteria:
inclusion criteria: * male or female, 19-75 years of age * diagnosed with type 2 diabetes mellitus * patients who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies; * metformin * sulphonylurea * thiazolidinedione * metformin and sulphonylurea * metformin and thiazolidinedione exclusion criteria: * has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following medications: 1. alpha glucosidase inhibitor or meglitinide within 30 days of screening; 2. insulin within 2 weeks prior to screening or insulin for longer than 1 week within 3 months of screening; 3. dpp-4 inhibitors within 30 days of screening; 4. regular use (\> 14 days) of drugs that directly affect gastrointestinal motility within 3 months of screening; 5. regular use (\> 14 days) of systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption within 3 months of screening; 6. glp-1 receptor agonist except exenatide within 3 months of screening; * diagnosed with type 1 diabetes mellitus or diabetic ketoacidosis; * type 2 diabetes by beta-cell dysfunction requiring insulin treatment * has ever used exenatide * pregnant or breast feeding patients * hepatic disease (defined by aspartate or alanine transaminase \>3.0 times the upper limit of normal * end-stage renal disease or severe renal impairment (creatinine clearance \< 30 ml/min)

Keywords: type 2 diabetes mellitus, t2dm, glp-1, glp-1 once weekly, exenatide
monitoring growth of preterm infants

Conditions: Prematurity

Summary: growth is poor in preterm infants, partly due to difficulty identifying when growth is slow. the investigators will examine the use of a computer program to try and identify periods of growth slowing in preterm babies, and compare those results to the usual assessments made on patient care rounds.

we wish to examine the use of a mathematical modeling system to see if it can detect poor growth better (and more quickly) than we can clinically. to do this, we need to know what the clinical team think about a baby's growth day-to-day. however, after rounds the fellow or nnp with fill in a sheet to say what the team thought about the baby's growth (was it okay, too slow, too fast etc.), and whether any changes were made to improve the baby's growth (e.g. increased feed volume, change in composition of feeds etc.). after the baby is discharged home, weight data from the emr will be entered into the program to try and identify times where growth slowed (or where growth was faster than expected). we will compare the results of the computer program and the record of the clinical teams thoughts on the ward round, to see if the computer program identified growth slowing more quickly than the clinical team did.

Eligibility criteria:
inclusion criteria: 1. birth weight \< 1750g gestational age \< 32w at birth exclusion criteria: 2. currently receiving parenteral nutrition or intravenous lipids

Keywords: growth, weight
study of circular rna treatment in patients with radiation induced xerostomia-1

Conditions: Radiation-Induced Xerostomia and Hyposalivation

Summary: this is a first-in-human clinical study to evaluate the safety, tolerability and efficacy of rxrg001 administered in the ducts of the parotid glands in adult patients with radiation-induced xerostomia (dry mouth) and hyposalivation (reduced saliva production). in part 1 of the study (open-label, single-arm), patients will receive unilateral administrations of rxrg001 in 3 single ascending dose cohorts and in 3 multiple ascending dose cohorts. part 2 of the study has a randomized, double-blind, placebo-controlled design. patients will receive bilateral administrations of rxrg001 in 3 multiple ascending dose cohorts.


Eligibility criteria:
inclusion criteria\* 1. at least 18 years of age 2. history of radiation treatment or chemoradiotherapy for head and neck cancer for stage 2 or higher 3. free from recurrence of your cancer and never have had another form of cancer for at least 2 years 4. suffering from xerostomia and/or hyposalivation and have xerostomia symptoms which were not resolved after treatment for at least 3 months 5. both parotid glands on imaging examination exclusion criteria\* 1. any active infection 2. heart failure, reduced kidney function or uncontrolled diabetes (hemoglobin a1c \>8%) 3. history of autoimmune diseases known to potentially affect the salivary glands 4. any malignancy, other than head and neck cancer within the past 3 years except for certain skin and cervical cancers 5. active smoker or use tobacco products or have a history of substance or alcohol abuse * other criteria apply

Keywords: radiation induced xerostomia first-in-human hyposalivation circular ribonucleic acid aquaporin 1
the people like us evaluation study

Conditions: HIV/AIDS; Sexually Transmitted Infection; Homosexuality; Health Behavior; Stigma, Social; Health Care Seeking Behavior

Summary: the study is a pragmatic, randomized controlled trial design to evaluate an online video series developed by a community-based organization in singapore for gay, bisexual and queer men. a total of 300 hiv-negative, gay, bisexual and queer men in singapore aged 18 to 29 years old will be recruited with the assistance of the partner community-based organization (cbo), action for aids singapore. recruitment will utilize both online and offline channels, and with the help of other cbos in singapore. participants should also not have watched the video prior to their participation in this study, which will be ascertained through a questionnaire. participants will subsequently be randomized into the intervention arm (n=150) and the control arm (n=150). the treatment group (n=150) will be assigned the intervention along with sexual health information via a pamphlet, while the control group (n=150) will be assigned only the sexual health information via a pamphlet. this will be conducted through block randomization.


Eligibility criteria:
inclusion criteria: * self-reported hiv-negative status, or unsure of hiv status * self-reported gay, bisexual or queer sexual orientation * self-reported male gender, regardless of sex assigned at birth * self-reported age of 18 to 29 years old at point of recruitment * singapore citizen or permanent resident at the point of recruitment * self-reported as never having watched an online video drama series by gayhealth.sg or action for aids in the last year exclusion criteria: * participants who have watched the people like us series prior to study * participants who have self-reported being hiv-positive * participants who are not english-literate * participants aged below 18 or above 29 at baseline recruitment

Keywords: hiv testing sti testing homophobia ehealth singapore
study of the metabolism of pyruvate and related problems in patients with lactic acidemia

Conditions: Mitochondrial Myopathy; MELAS Syndrome; Lactic Acidosis

Summary: objectives: i. study the metabolism of pyruvate and related problems in patients with lactic acidemia. ii. define the nature of the metabolic defect.

protocol outline: patients fast for 6 hours. glucagon im is administered after the 6 hour fast. glucose level is measured at 0, 15, 30, 45, 60, and 90 minutes. in children of sufficient size, alanine and lactic acid should also be measured at each or most of these time points. fasting continues for at least 18 hours. glucagon im is administered again at end of fast. glucose level is measured at time 0, 15, 30, 45, 60, and 90 minutes.

Eligibility criteria:
protocol entry criteria: * diagnostically documented elevation in lactate, pyruvate, and/or alanine levels in lactic acidemia patients

Keywords: melas syndrome inborn errors of metabolism lactic acidosis mitochondrial myopathy rare disease